Colorectal Cancer, Gastric Cancer, Nasopharyngeal Carcinoma, Prostate Cancer, Sarcoma, Triple Negative Breast Cancer
Conditions
Keywords
NKG2D, gamma, delta, T cell, CAR, chimeric antigen receptor, solid tumour, cancer immunotherapy, adoptive cell transfer
Brief summary
This clinical trial is an open-label, single-centre, dose escalation, phase I study designed to investigate the safety and tolerability of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Gamma Delta (γδ) T Cells (CTM-N2D) in Subjects with Relapsed or Refractory Solid Tumour. The study objectives of this phase I study are to determine the safety, activity and the safe dose of haploidentical or allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells given four times weekly in patients with relapsed or refractory solid tumors of different types.
Detailed description
CTM-N2D-101 is a phase I dose-escalation study to evaluate the safety of CTM-N2D and the feasibility to produce CTM-N2D for three target dose levels between 3x10\^8 - 3x10\^9 per infusion will be tested. Four doses will be given at an interval of a week into subjects with relapsed or refractory solid tumors. A typical 3+3 design will be used to determine the safe regimen basing on the incidence of dose-limiting toxicity (DLT). The identified safe regimen will be used for further phase II studies for selected indications.
Interventions
BIOLOGICALAdoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
Sponsors
CytoMed Therapeutics Pte Ltd
Study design
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
NONE
Intervention model description
The study consisT of 3 + 3 dose escalation study design with 3 distinct dose level. The first dose level will be at 3 x 10\^8 chimeric antigen receptor (CAR) grafted γδ T cells per infusion. The second dose level will be at 1 x 10\^9 CAR-γδT cells per infusion. The third dose level will be increased to 3 x 10\^9 cells CAR-γδT cells. Each cycle of therapy will consist of 4 intravenous infusions, given 7 days apart.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men or women ≥18 years old. * Patient with specific cancer indications (see below). * Disease must be measurable according to the corresponding guidelines. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 or 2. * Patient with adequate bone marrow reserve (Haemoglobin ≥10g/dl, Absolute Neutrophil Count (ANC)≥1,500/mm3, Platelet≥100,000/mm3), hepatic function (Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \< 3x upper limit of normal), renal function (serum creatinine \< 120 µmol/L) and cardiac function (Left ventricular ejection fraction of ≥50% by ECHO). * Patient must already have a previous tumour biopsy to confirm the disease. * Patient must agree to sign the informed consent form (ICF). Cancer-specific inclusion criteria of subject: * Colorectal cancer: A documented metastatic colorectal adenocarcinoma and having received, being intolerant to or being unfit for at least two prior standard cancer therapy regimens as part of their primary treatment regimen or part of their treatment for management of recurrent/persistent disease. * Breast cancer: A metastatic triple-negative breast cancer and having received at least two prior cancer therapy regimens as part of their treatment for management of recurrent/persistent disease. * Sarcoma, nasopharyngeal cancer, prostate cancer or gastric cancer: A metastatic cancer and having received at least two prior cancer therapy regimens as part of their treatment for management of recurrent/persistent disease.
Exclusion criteria
* Patients with a tumour metastasis in the central nervous system. * Patients who receive or are to receive any investigational product within the 4 weeks before the planned day for the first CTM-N2D administration. * Patients who receive or are to receive chemotherapy within the 8 weeks before the planned day for the first CTM-N2D administration. * Patients who are planned to receive concurrent growth factor, systemic steroid or other immunosuppressive therapy or cytotoxic agent. * Patients who underwent major surgery within 4 weeks before the planned day for the first CTM-N2D administration. * Patients who have active infections necessitating the use of antibiotics/antivirals treatment. * Patients with a history of autoimmune disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients with Dose Limiting Toxicity | 6 months | The primary endpoint of this dose-escalation study will be the occurrence of dose-limiting toxicities (DLTs) during 4 cycles of treatment and the week after treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Occurence of adverse events during therapy | 6 months | A secondary outcome is to observe for the occurence of any adverse events (AEs) and serious adverse events (SAEs) during 4 cycles of treatment and the week after treatment |
| Observation of clinical efficacy | 6 months to 2 years | A secondary outcome is to observe for the occurrence of objective clinical response at d31, M3, M6, M9, M12, M18 and M24 after the start of 1st cycle of treatment (assessed according to RECIST criteria, version 1.1) |
| Observation for progression-free survival | up to 2 years | A secondary outcome is to observe for progression-free survival (PFS) and after the start of 1st cycle of treatment |
| Observation for duration of response | Up to 2 years | A secondary outcome is to observe the duration of response in patients with objective response up to M24, After the start of 1st cycle of treatment |
Countries
Malaysia
Contacts
Primary ContactPeter Choo
Backup ContactWee Kiat Tan
Outcome results
None listed